BESIVANCE^® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria^1-3:

Important Risk Information about BESIVANCE^®

Besivance should not be injected into the eye or used systemically. As with other anti-infectives, prolonged use of Besivance may result in overgrowth of non-susceptible organisms leading to super-infection. Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with Besivance. At the first sign of an allergic reaction, patients should discontinue use immediately and contact their physician.

The most common adverse events in clinical trials were conjunctival redness, blurred vision, eye pain, eye irritation, eye pruritus and headache, reported in approximately 1-2% of patients one year and older. Safety and effectiveness in infants below one year of age have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see the full prescribing information for BESIVANCE.

References: 1. BESIVANCE^® Prescribing Information, April 2009. 2. Karpecki P, DePaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehiclecontrolled, 5-day efficacy and safety study. Clin Ther. 2009;31(3):514-526. 3. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25:1159-1169. 4. Morris TW, Haas W, Brunner LS, et al. Clinical efficacy of besifloxacin ophthalmic suspension; integrated microbiological results of 3 trials for topical treatment of bacterial conjunctivitis. Presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); May 3-7, 2009; Ft Lauderdale, FL.